Clinical Trials Logo

Secondary Glioblastoma clinical trials

View clinical trials related to Secondary Glioblastoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04145115 Suspended - Clinical trials for Glioblastoma, IDH-Wildtype

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Start date: December 24, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden). Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).